Clinical Trials

90 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

21 enrolled

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT04512534 2026-04-02

Sincerely20

51 enrolled

Lymphoma, T-Cell, Peripheral

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT07300514 2026-03-31

T-START-M1

Phase 3 Recruiting

136 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT06519526 2026-03-24

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

25 enrolled

Lymphoma, T-Cell, Peripheral

NCT07270861 2026-03-24

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

3,000 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07164560 2026-03-17

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

45 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07470996 2026-03-13

T-START-NR

58 enrolled

Lymphoma, T-Cell, Peripheral

NCT07414758 2026-02-24

T-START-M1

Phase 3 Recruiting

68 enrolled

Lymphoma, T-Cell, Peripheral

NCT06089941 2026-02-20

PTCL-SEQ

Active not recruiting

45 enrolled

Lymphoma, T-Cell, Peripheral

NCT06131801 2026-02-18

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

LymphoidMyeloidOther hematologic neoplasm

30 enrolled

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06630091 2026-02-17

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT02362997 2026-02-12

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Phase 2/3 Recruiting

40 enrolled

Lymphoma, T-Cell, Peripheral

NCT07353840 2026-01-20

T-START-CR

160 enrolled

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07093710 2025-12-31

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

101 enrolled

Lymphoma, T-Cell, Peripheral

NCT07253129 2025-12-23

T-START-PR

88 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07288814 2025-12-17

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

43 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07283822 2025-12-16

Amping up With PemJAK

Phase 2 Not yet recruiting

53 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

31 enrolled

Phase 1/2 Active not recruiting

Lymphoma, T-Cell, Peripheral

NCT02223208 2025-12-02

FIL_PTCL13

89 enrolled

Phase EARLY_PHASE1 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT07162012 2025-12-02

Anti-EBV TCR-T

24 enrolled

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT07258680 2025-12-02

BrEto-TCL

114 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

48 enrolled

Lymphoma, T-Cell, Peripheral

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

20 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Phase 1 Completed

23 enrolled

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06160843 2025-09-05

POLAR

24 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma, T-Cell, Peripheral

NCT03719105 2025-08-08

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

40 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Leukemia, Large Granular Lymphocytic

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

56 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

71 enrolled

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT07072221 2025-07-18

Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

Phase NA Recruiting

40 enrolled

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

35 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral

NCT05290155 2025-06-06

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Phase 1 Completed

14 enrolled

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06244368 2025-05-14

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

115 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT06963632 2025-05-09

JOYCE

Not yet recruiting

1,000 enrolled

Lymphoma, T-Cell, Peripheral

NCT03964480 2025-05-06

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

1,000 enrolled

Phase 1 Active not recruiting

Lymphoma, T-Cell, Peripheral, Rare Diseases

NCT05377827 2025-04-29

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

6 enrolled

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Sezary Syndrome, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT06941688 2025-04-24

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

17 enrolled

Lymphoma, T-Cell, Peripheral

NCT06914037 2025-04-06

COURAGE

24 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

32 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT06855823 2025-03-04

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Phase 1/2 Recruiting

33 enrolled

DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Phase 2 Completed

6 enrolled 11 charts

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

NCT06151106 2025-02-19

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

33 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT06757387 2025-01-03

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

45 enrolled

Lymphoma, T-Cell, Peripheral

NCT05958719 2024-12-30

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

37 enrolled

Lymphoma, T-Cell, Peripheral

NCT06739265 2024-12-18

Golidocitinib Plus CHOP in Newly Diagnosed PTCL

Phase 1/2 Recruiting

68 enrolled

Phase 1 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06712173 2024-12-02

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

33 enrolled